HeartCare Medical-B (06609.HK) Surges Over 6% on H1 Profit Turnaround with RMB 50.94 Million Net Income

Intelligent Finance APP learned that HeartCare-B (06609) rose over 6%.，As of press time, up 6.21%, trading at HK$59.9, with a turnover of HK$17.3838 million.

On the news front, HeartCare released its mid-term performance for 2025. The group achieved revenue of RMB 186 million (same unit hereinafter), representing a year-on-year increase of 44.4%; gross profit reached RMB 127 million, up 53.9% year-on-year; net profit attributable to shareholders was RMB 50.938 million, turning losses into profits year-on-year. The announcement stated that these improvements were mainly attributed to increased revenue from newly launched hemorrhagic stroke treatment devices, rising sales of ischemic stroke treatment devices and other hemorrhagic stroke treatment devices driving business growth, as well as an overall decrease in the company's expense ratio.

Moreover, the company continuously drives the upgrade of its neurointervention business, focusing on differentiated therapeutic devices. The sales of ischemic stroke treatment devices and other access devices increased by 38.3% and 29.2%, respectively. The revenue driven by hemorrhagic stroke treatment devices rose by approximately 37.7 million yuan compared to the same period in 2024, primarily due to the launch of new devices.